Guidelines for the management of inflammatory bowel disease in adults

@article{Mowat2011GuidelinesFT,
  title={Guidelines for the management of inflammatory bowel disease in adults},
  author={Craig Mowat and Andrew Cole and Alastair Windsor and Tariq Ahmad and Ian Arnott and Richard J. Driscoll and Sally G. Mitton and T R Orchard and Matthew David Rutter and Lisa Younge and Charlie W. Lees and Gwo-tzer Ho and Jack Satsangi and Stuart L Bloom},
  journal={Gut},
  year={2011},
  volume={60},
  pages={571 - 607}
}
The management of inflammatory bowel disease represents a key component of clinical practice for members of the British Society of Gastroenterology (BSG). There has been considerable progress in management strategies affecting all aspects of clinical care since the publication of previous BSG guidelines in 2004, necessitating the present revision. Key components of the present document worthy of attention as having been subject to re-assessment, and revision, and having direct impact on… 
The role of budesonide in the management of Crohn's disease
TLDR
An overview of Crohn's disease and the current strategies used in its pharmacological management is provided, placing specific focus on the role of budesonide in the treatment pathway.
Challenges in the Diagnosis and Management of Inflammatory Bowel Disease in the Elderly
  • S. Taleban
  • Medicine
    Current Treatment Options in Gastroenterology
  • 2015
TLDR
A vast number of incident CD and UC cases in elderly have been treated with 5-aminosalicylic acid agents and do not require the use of immune modifying agents or biologics.
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults
TLDR
Comprehensive up-to-date guidance is provided regarding indications for, initiation and monitoring of immunosuppressive therapies, nutrition interventions, pre-, peri- and postoperative management, as well as structure and function of the multidisciplinary team and integration between primary and secondary care.
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020
TLDR
This English version was produced and modified based on the existing updated guidelines in Japanese regarding indications for proceeding with the diagnosis and treatment of inflammatory bowel disease.
[Second Korean Guideline for the Management of Ulcerative Colitis].
  • C. Choi, W. Moon, D. Han
  • Medicine
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • 2017
TLDR
This guideline encompasses treatment of active colitis, maintenance of remission, and indication of surgery for UC, and was generally made by the adaptation of several foreign guidelines as was the first edition.
[Second Korean Guidelines for the Management of Crohn's Disease].
TLDR
These guidelines were developed by using mainly adaptation methods, and encompass induction and maintenance treatment of CD, treatment based on disease location, treatment ofCD complications, including stricture and fistula, surgical treatment, and prevention of postoperative recurrence.
The historical role and contemporary use of corticosteroids in inflammatory bowel disease.
TLDR
The historical background to steroid usage in IBD is discussed, and a brief review of the literature on side effects of corticosteroid treatment as relevant to IBD patients is provided, including identification of 'at-risk' populations.
Using corticosteroids appropriately in inflammatory bowel disease: a guide for primary care.
  • K. Barrett, S. Saxena, R. Pollok
  • Medicine
    The British journal of general practice : the journal of the Royal College of General Practitioners
  • 2018
TLDR
Patients with IBD flare-ups usually present with a combination of diarrhoea, abdominal pain, or rectal bleeding, although atypical presentations including weight loss, anaemia, and failure to thrive can occur, and the severity of symptoms may not reflect the severityof inflammation, particularly in children.
French national consensus clinical guidelines for the management of ulcerative colitis.
Biologic agents in the management of inflammatory bowel disease: is it worth it?
TLDR
The heavy burden that IBD imposes on patients in turn leads to substantial financial costs for the Canadian healthcare system, and these costs include both direct costs associated with treating the disease and indirect costs such as lost productivity and time missed from work.
...
...

References

SHOWING 1-10 OF 472 REFERENCES
Guidelines for the management of inflammatory bowel disease in adults
TLDR
These guidelines, commissioned by the Clinical Services’ Committee of the British Society of Gastroenterology, provide an evidence based document describing good clinical practice for investigation and treatment of patients with IBD in the United Kingdom.
Clinical uniformity of inflammatory bowel disease at presentation and during the first year of disease in the north and south of Europe
TLDR
The standard of diagnosis and clinical features of IBD are similar in specialist centres throughout Europe so providing a valid basis for this aspect of collaborative epidemiological or other studies.
Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus.
TLDR
This document sets out the current Consensus reached by a group of international experts in the fields of endoscopy and IBD at a meeting held in Brussels, 12-13th December 2008, organised jointly by the European Crohn's and Colitis Organisation (ECCO) and the Organisation Mondiale d'Endoscopie Digestive (OMED).
European evidence-based Consensus on the management of ulcerative colitis: Current management.
A meta-analysis on the influence of inflammatory bowel disease on pregnancy
TLDR
The study has shown a higher incidence of adverse pregnancy outcomes in patients with IBD, who should be treated as a potentially high-risk group.
Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery
TLDR
Although immunosuppressants have been used more frequently over the last 25 years, there was no significant decrease of the need for surgery, or of intestinal complications of Crohn’s disease.
Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. EC-IBD Study Group.
TLDR
The standard of diagnosis and clinical features of IBD are similar in specialist centres throughout Europe so providing a valid basis for this aspect of collaborative epidemiological or other studies.
The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review
TLDR
The efficacy of azathioprine is reasonably well sustained over five years and there was no difference in relapse rates between Crohn's disease and ulcerative colitis.
European evidence based consensus on the diagnosis and management of Crohn’s disease: current management
This second section of the European Crohn’s and Colitis Organisation (ECCO) Consensus on the management of Crohn’s disease concerns treatment of active disease, maintenance of medically induced
The Management of Acute Severe Colitis: ACPGBI Position Statement
TLDR
This position statement sets out to examine the current literature on this condition and to provide an evidence-base upon which practitioners can base individual management of severe colitis.
...
...